Abbvie
Clinical trials sponsored by Abbvie, explained in plain language.
-
New injection trial offers hope for Crohn's disease sufferers
Disease control OngoingThis study is testing whether risankizumab injections can help control symptoms and reduce intestinal inflammation in adults with moderate to severe Crohn's disease. Participants will receive either the study drug or a placebo injection for up to 24 weeks, followed by an extended…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 03, 2026 19:41 UTC
-
Head-to-Head showdown: injection vs. pill for psoriasis relief
Disease control OngoingThis study directly compares two already-approved medications for adults with moderate plaque psoriasis. Participants will receive either an injection every 12 weeks or take a daily pill for up to 44 weeks. The goal is to see which treatment is more effective at clearing skin and…
Phase: PHASE4 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 03, 2026 19:40 UTC
-
Major trial tests new pill to tame severe eczema itch and rash
Disease control OngoingThis large, late-stage study tested whether a daily pill called upadacitinib, taken alongside a standard steroid skin cream, is effective and safe for controlling moderate to severe eczema (atopic dermatitis). It enrolled over 1500 teens and adults whose eczema was not well-contr…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New antibody therapy tested for Tough-to-Treat blood cancer
Disease control OngoingThis study is testing an experimental antibody drug called TNB-383B for people with multiple myeloma that has come back or stopped responding to at least three previous treatments. Researchers are giving the drug to 220 participants to find the safest and most effective dose, and…
Phase: PHASE1, PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New hope for tough cancers: first test of experimental drug begins
Disease control OngoingThis is the first study in people to test the safety and early effectiveness of an investigational drug called ABBV-400 for adults with advanced solid tumors that have stopped responding to standard treatments. The trial will find the best dose of ABBV-400 given alone and will al…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Targeted therapy trial offers new hope for Tough-to-Treat lung cancer
Disease control OngoingThis study is testing an experimental drug called telisotuzumab vedotin for people with advanced non-small cell lung cancer that has a specific biomarker called c-Met. The goal is to see if the drug can shrink tumors and control the cancer in patients who have already tried other…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Experimental drug targets specific protein in advanced lung cancer
Disease control OngoingThis early-stage study is testing whether a new drug called cofetuzumab pelidotin is safe and effective for people with recurrent non-small cell lung cancer that has a specific protein called PTK7. The trial involves 65 participants whose cancer has returned after previous treatm…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
First human tests begin for experimental cancer immunotherapy duo
Disease control OngoingThis is an early-stage study to find the safest and most effective doses of two new immunotherapy drugs, ABBV-927 and ABBV-181, for people with advanced solid tumors. The study will test the drugs alone and together in about 163 participants whose cancer has progressed after stan…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New drug combo aims to tame tough blood cancer
Disease control OngoingThis early-stage study is testing whether adding an experimental drug called etentamig to standard multiple myeloma treatments is safe and more effective. It involves about 283 adults whose cancer has returned or stopped responding to previous therapies. Researchers will try diff…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New hope for kids with untreatable bowel disease
Disease control OngoingThis study is testing whether a daily pill called upadacitinib can help control ulcerative colitis in children and teenagers whose disease hasn't responded to standard treatments. About 110 young participants with moderate-to-severe symptoms will take the medication for up to six…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Tracking a lifeline drug for frail blood cancer patients
Disease control OngoingThis study is collecting real-world information on how well the drug venetoclax works for adults with acute myeloid leukemia (AML) who are too old or frail for standard intensive chemotherapy. About 200 participants across Canada will take venetoclax pills daily as prescribed by …
Sponsor: AbbVie • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
One shot could replace monthly eye injections for vision loss
Disease control OngoingThis study is testing a one-time gene therapy injection for wet age-related macular degeneration (wet AMD), a leading cause of vision loss in older adults. The goal is to see if this single treatment can work as well as or better than the current standard of care, which requires …
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
First patients test new oral drug for Tough-to-Treat blood cancers
Disease control OngoingThis is the first human study of an experimental oral drug called ABBV-101 for people with advanced B-cell blood cancers that have returned or not responded to previous treatments. The main goals are to find a safe dose and see how the body processes the drug, while also checking…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New psoriasis drug study aims to clear skin and restore quality of life
Disease control OngoingThis study observes how well the approved medication risankizumab works for people recently diagnosed with moderate plaque psoriasis in real-world Greek clinics. About 250 participants who haven't tried advanced treatments will be followed for two years while taking risankizumab …
Sponsor: AbbVie • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New drug trial aims to tame rare, dangerous blood vessel disease
Disease control OngoingThis study is testing whether a medication called upadacitinib can help people with Takayasu arteritis stay in remission longer and reduce their need for steroid medications. It involves adults who have recently had a flare-up of this rare autoimmune disease that causes inflammat…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New drug tested for painful skin condition after other treatments fail
Disease control OngoingThis study is testing whether an investigational drug called lutikizumab can help adults with moderate-to-severe hidradenitis suppurativa, a painful inflammatory skin condition. The research focuses on people who haven't gotten enough benefit from previous anti-TNF treatments, wi…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New Parkinson's treatment tested in Real-Life french study
Disease control OngoingThis study is looking at how well an approved Parkinson's medication called foslevodopa/foscarbidopa works in everyday clinical practice. About 200 French adults with advanced Parkinson's disease will receive the medication via under-skin infusion as prescribed by their doctors. …
Sponsor: AbbVie • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Experimental cancer drug enters first human trials for Tough-to-Treat gynecologic cancers
Disease control OngoingThis early-stage study is testing a new drug called IMGN151 in patients with recurrent gynecologic cancers that have returned after previous treatments. The main goals are to determine the safest dose, understand how the drug behaves in the body, and see if it shows any early sig…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for RA patients who failed First-Line treatment
Disease control OngoingThis study compares two medications, upadacitinib and adalimumab, for adults with moderate to severe rheumatoid arthritis who didn't respond well to a previous TNF inhibitor drug. About 480 participants worldwide will take one of the two drugs along with their current methotrexat…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug tested against eight tough cancers
Disease control OngoingThis early-stage study is testing an experimental drug called ABBV-400 in adults with advanced solid tumors that have spread or cannot be removed by surgery. It includes eight specific cancer types, such as liver, pancreatic, and certain breast cancers. The main goals are to chec…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
New drug shows promise for Long-Term control of debilitating bowel disease
Disease control OngoingThis study is testing whether the drug risankizumab can safely keep ulcerative colitis under control for a year or more in people who initially responded to it. It involves 1,242 participants who will receive either the drug or a placebo to compare results. The main goals are to …
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New Two-Pronged attack on recurring ovarian cancer
Disease control OngoingThis study is testing a two-part treatment for ovarian cancer that has come back after initial chemotherapy. It combines a standard chemotherapy drug with a newer, targeted drug designed to attack cancer cells with a specific marker. After the combination phase, patients continue…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Doctors track Long-Term safety of Vision-Saving eye implant
Disease control OngoingThis study is observing the long-term safety and effectiveness of the OZURDEX eye implant in patients with diabetic macular edema (DME) in China. The implant slowly releases medication to reduce swelling in the retina. About 110 patients who are already prescribed OZURDEX by thei…
Sponsor: AbbVie • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New hope for taming a troubling gut disease
Disease control OngoingThis study is testing an investigational drug called lutikizumab for adults with moderate-to-severe ulcerative colitis, a chronic inflammatory bowel disease. It aims to see if lutikizumab is safe, effective, and works as well as or better than an existing treatment (adalimumab). …
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Tracking a promising leukemia drug in everyday practice
Disease control OngoingThis study is observing how well the drug venetoclax works for people with acute myeloid leukemia (AML) during their normal medical care in Israel. It will follow 100 patients to see how long they live, if their cancer goes into remission, and how their quality of life changes. T…
Sponsor: AbbVie • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New hope for women suffering from debilitating endometriosis pain
Disease control OngoingThis study is testing whether adding the medication elagolix to standard birth control pills works better for controlling moderate to severe pain from endometriosis. About 800 women with surgically confirmed endometriosis will participate. For the first 3 months, participants wil…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Extended trial tests promising drug for chronic bowel disease
Disease control OngoingThis study aims to understand the long-term safety and effectiveness of the drug upadacitinib for adults with ulcerative colitis. It is for people who have already participated in related earlier studies, either because their condition did not improve enough or they lost their re…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Major trial tests promising pill to restore skin color in vitiligo
Disease control OngoingThis large, late-stage study is testing if a daily pill called upadacitinib can help repigment skin in people with non-segmental vitiligo, an autoimmune condition that causes white patches. About 614 participants will be randomly assigned to receive either the active drug or a pl…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New hope for Kids' itchy skin: major trial tests eczema pill
Disease control OngoingThis study is testing whether adding an oral medication called upadacitinib to standard steroid creams is safe and works better for controlling moderate to severe eczema in young children in Japan. About 99 children aged 2 to 11 will take either the real pill or a placebo (sugar …
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New hope for diabetic eye patients: study tests steroid implant after standard treatment fails
Disease control OngoingThis study follows patients with diabetic macular edema (DME), a vision-threatening eye swelling, who didn't respond well to standard anti-VEGF injections. Doctors will observe how these patients do when switched to a slow-release steroid implant (DEX-I) in their regular clinical…
Sponsor: AbbVie • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Experimental drug offered for devastating rare brain diseases
Disease control NO_LONGER_AVAILABLEThis program provided early access to an investigational drug called fosigotifator for people with vanishing white matter disease and Cree leukoencephalopathy—two rare, serious brain disorders. It was designed to make the treatment available to eligible patients before it receive…
Sponsor: AbbVie • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
New hope for tough blood cancers: first human trial begins
Disease control OngoingThis is a very early-stage study to test the safety and find the right dose of a new oral drug called ABBV-453 for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or stopped responding to at least two prior treatments. Particip…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Cancer patients get extended access to promising drug in safety Follow-Up
Disease control OngoingThis study allows patients already receiving venetoclax in other trials to continue treatment if they are benefiting and tolerating it well. The main goal is to collect long-term safety information by tracking any side effects. It includes about 165 patients with various blood ca…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
First human test of new drug for Tough-to-Treat cancers begins
Disease control OngoingThis is the first human study of an experimental drug called ABBV-706 for people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see how the body processes the drug, while also checking for early signs tha…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New hope for tough blood cancer: testing combo therapy in global trial
Disease control OngoingThis study is for adults with myelofibrosis, a rare blood cancer, that has come back or not improved after prior treatment. It compares a new two-drug combination (navitoclax + ruxolitinib) against the current best available treatments to see which is better at reducing spleen si…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
Two-Year watch: can this pill keep severe eczema at bay?
Disease control OngoingThis study is observing how well the already-approved oral medication upadacitinib (RINVOQ) works for controlling moderate-to-severe eczema over two years in real-world medical settings. It involves about 770 adolescents and adults in Germany who are already prescribed this medic…
Sponsor: AbbVie • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC
-
One-Shot gene therapy could free patients from monthly eye injections
Disease control OngoingThis study is testing a potential one-time gene therapy called RGX-314 for diabetic retinopathy, a leading cause of vision loss. The goal is to see if a single injection can slow or reverse the eye damage caused by diabetes, reducing the need for the frequent eye injections that …
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC
-
New hope for Tough-to-Treat colon cancer
Disease control OngoingThis study is testing a new drug called ABBV-400, given with standard chemotherapy drugs, for adults with advanced colorectal cancer that has spread and cannot be removed by surgery. The goal is to find the safest and most effective dose and see if this combination can help contr…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC
-
Experimental leukemia drug offered to patients before official approval
Disease control NO_LONGER_AVAILABLEThis program provided early access to an investigational drug called ABBV-787 for people with acute myeloid leukemia before it received full regulatory approval. It was designed for eligible patients who had no other suitable treatment options and could not join ongoing clinical …
Sponsor: AbbVie • Aim: Disease control
Last updated Mar 16, 2026 15:24 UTC
-
New shot aims to tame severe eczema Flare-Ups
Disease control OngoingThis study is testing a new injectable drug called lutikizumab for people with moderate to severe atopic dermatitis (eczema). About 80 participants will receive either the drug or a placebo via injection every other week for 16 weeks, followed by the drug for another 32 weeks. Th…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Mar 16, 2026 15:24 UTC
-
Can fillers restore your face after weight loss?
Symptom relief OngoingThis study is testing how safe and effective JUVÉDERM facial filler products are for adults who have lost weight and want to improve their facial volume and skin quality. It involves 75 participants who will receive at least two different filler products. Researchers will measure…
Phase: PHASE4 • Sponsor: AbbVie • Aim: Symptom relief
Last updated Apr 02, 2026 14:58 UTC
-
Do new migraine pills actually satisfy patients?
Symptom relief OngoingThis study aims to see how satisfied patients are with two already-approved migraine medications, ubrogepant and atogepant, when used in everyday life. It will follow about 200 adults in Israel who are prescribed one of these drugs by their doctor for 90 days. The main goal is to…
Sponsor: AbbVie • Aim: Symptom relief
Last updated Apr 02, 2026 14:56 UTC
-
CoolSculpting elite under review: safety and satisfaction study launches
Symptom relief OngoingThis study aims to collect safety information and patient satisfaction data for the CoolSculpting Elite system, a non-surgical fat reduction treatment. Researchers are gathering information from 102 people who received treatments on their chin, inner thighs, or back/bra areas. Th…
Phase: PHASE4 • Sponsor: AbbVie • Aim: Symptom relief
Last updated Mar 23, 2026 15:15 UTC
-
Beauty boost: does a mix of injectables and procedures make people happier with their looks?
Symptom relief OngoingThis study aims to find out how satisfied people are with their overall face and neck appearance after receiving a combination of common cosmetic treatments. It will enroll 130 diverse participants who will receive treatments like Botox, Juvéderm fillers, Kybella, CoolSculpting, …
Phase: PHASE4 • Sponsor: AbbVie • Aim: Symptom relief
Last updated Mar 19, 2026 14:55 UTC
-
First human tests begin for new drug candidate
Knowledge-focused OngoingThis is a very early study to test the safety of a new drug called ABBV-142 in healthy people. Researchers will give different single doses to 73 healthy adult volunteers to see how the body handles the drug and if it causes any side effects. The study also includes a specific gr…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Knowledge-focused
Last updated Apr 03, 2026 14:41 UTC
-
First human tests begin for new drug candidate
Knowledge-focused OngoingThis is an early-stage study to check the safety and see how the body processes a new drug called ABBV-8736. It involves 24 healthy adult volunteers who will receive the drug or a placebo through an IV. The main goal is to understand the drug's side effects and how it moves throu…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Knowledge-focused
Last updated Apr 02, 2026 14:57 UTC
-
First human tests begin for new drug candidate
Knowledge-focused OngoingThis early-stage study aims to check the safety and basic effects of a new drug called ABBV-701 in healthy people. It will involve about 100 healthy adults from Western and Asian backgrounds. Researchers will give participants different single doses to see how the drug moves thro…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:43 UTC
-
Scientists test drug mix in healthy volunteers
Knowledge-focused OngoingThis early-stage study aims to understand how a common antifungal drug (itraconazole) affects how the body processes an experimental medication called ABBV-932. It involves about 20 healthy adult volunteers who will take both drugs. The main goal is to measure drug levels in the …
Phase: PHASE1 • Sponsor: AbbVie • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:12 UTC
-
Scientists test how food affects new Drug's absorption
Knowledge-focused OngoingThis is an early, small study to understand how the body absorbs and processes a new tablet drug called ABBV-722. It involves 11 healthy volunteers and tests whether taking the drug with or without food changes how much of it gets into the bloodstream. The main goal is to gather …
Phase: PHASE1 • Sponsor: AbbVie • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:12 UTC
-
Fibroid drug hair loss study canceled before launch
Knowledge-focused TerminatedThis study aimed to track hair changes in women taking Oriahnn for uterine fibroids. Researchers planned to follow 1,600 women for two years to understand how often hair loss occurs, when it starts, and if it improves. The study was withdrawn before any participants were enrolled…
Sponsor: AbbVie • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:34 UTC
-
First human tests for new Drug's absorption
Knowledge-focused OngoingThis is an early, small study to understand how the body absorbs different pill versions of an experimental drug called ABBV-932. It will test how much of the drug gets into the bloodstream and if taking it with food changes that. The study involves 9 healthy adult volunteers to …
Phase: PHASE1 • Sponsor: AbbVie • Aim: Knowledge-focused
Last updated Mar 09, 2026 14:24 UTC